|
Dr. Kabakoff is the current President and CEO of Strategy Advisors which he established in 2001 to provide business and strategic advisory services to life sciences companies. Prior to its acquisition by Cephalon Inc. in June 2005 Dr. Kabakoff served as Chairman and Chief Executive Officer of Salmedix Inc. a company he co-founded in 2001 to develop novel oncology drugs. From 1996 to September 2000 Dr. Kabakoff held executive management positions with Dura Pharmaceuticals a specialty pharmaceutical company acquired by Elan Pharmaceuticals. Prior to joining Dura Dr. Kabakoff was Chairman and Chief Executive Officer of Corvas International a biopharmaceutical firm focused on cardiovascular and inflammatory diseases. He has also held senior management positions with Hybritech Inc. a pioneer in the field of monoclonal antibodies which was acquired by Eli Lilly & Co. in 1986. Dr. Kabakoff received his Ph.D. in Chemistry from Yale University and his B.A. in Chemistry from Case Western Reserve University. Dr. Kabakoff serves on the Boards of Intermune Inc. Rx3 Pharmaceuticals and Allylix Inc. | 